Abstract:Mitochondrial drug delivery has attracted increasing attention in various mitochondrial dysfunction-associated disorders such as cancer owing to the important role of energy production. Herein, we report a lysosomal pH-activated mitochondrial-targeting polymer nanoparticle to overcome drug resistance by a synergy between mitochondrial delivery of doxorubicin (DOX, an anticancer drug) and erlotinib-mediated inhibition of drug efflux. The obtained nanoparticles, DE-NPs could maintain negative charge and have long blood circulation while undergoing charge reversal at lysosomal pH after internalization by cancer cells. Thereafter, the acidity-activated polycationic and hydrophobic polypeptide domains boost lysosomal escape and mitochondrial-targeting drug delivery, leading to mitochondrial dysfunction, ATP suppression, and cell apoptosis. Moreover, the suppressed ATP supply and erlotinib enabled dual inhibition of drug efflux by DOX-resistant MCF-7/ADR cells, leading to significantly augmented intracellular DOX accumulation and a synergistic anticancer effect with a 17-fold decrease of IC50 relative to DOX. In vivo antitumor study demonstrates that DE-NPs efficiently suppressed the tumor burden in MCF-7/ADR tumor-bearing mice and led to negligible toxicity. This work establishes that a combination of mitochondrial drug delivery and drug efflux inhibition could be a promising strategy for combating multidrug resistance.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c03196?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c03196</a>.Synthetic scheme of PKCF; 1H NMR and FTIR spectra of polymers; DLS and zeta potentials of PKCF and D-NPs; cytotoxicity of PKCF NPs; cytotoxicity of Erlo and NPs against MCF-7 cells; cellular uptake of different formulations; cell cycle analysis; and H&E staining images of organs after treatment (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c03196/suppl_file/am1c03196_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Dual Aptamer Modified Dendrigraft Poly-L-lysine Nanoparticles for Overcoming Multi-Drug Resistance Through Mitochondrial Targeting.

Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance

Polyplexes by Polymerized Dequalinium and Bifunctional Aptamer for Mitochondrial Targeting Drug Release to Overcome Drug Resistance

Mitochondrial Targeting and Ph-Responsive Nanogels for Co-Delivery of Lonidamine and Paclitaxel to Conquer Drug Resistance.

Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance.

Overcoming Chemotherapy Resistance Via Simultaneous Drug-Efflux Circumvention and Mitochondrial Targeting

Long-Circulating Amphiphilic Doxorubicin For Tumor Mitochondria-Specific Targeting

Coordinating Biointeraction and Bioreaction of a Nanocarrier Material and an Anticancer Drug to Overcome Membrane Rigidity and Target Mitochondria in Multidrug‐Resistant Cancer Cells

Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy

Stepwise Dual Targeting and Dual Responsive Polymer Micelles for Mitochondrion Therapy.

Mitochondria and Nucleus Dual Delivery System to Overcome DOX Resistance

Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer

Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anti-cancer Drug to Overcome Tumor Multidrug Resistance.

Mitochondrial Targeted Doxorubicin Derivatives Delivered by ROS-responsive Nanocarriers to Breast Tumor for Overcoming of Multidrug Resistance.

Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition

Mitochondria-Targeted Chimeric Peptide for Trinitarian Overcoming of Drug Resistance.

DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells.

Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.

Mitochondrial Surface Engineering for Multidrug Resistance Reversal.

Tumor-Penetrating and Mitochondria-Targeted Drug Delivery Overcomes Doxorubicin Resistance in Lung Cancer

Mitochondrial-targeting Nanoprodrugs to Mutually Reinforce Metabolic Inhibition and Autophagy for Combating Resistant Cancer.